This article aims to inform primary care providers about the mechanism of action of one class of AOMs, glucagon-like peptide 1 receptor agonists (GLP-1RAs), in weight loss and longer-term maintenance of weight loss, and the efficacy and safety of this treatment class
Yes, often stronger than before
Tirzepatide to semaglutide The reverse switch, tirzepatide to semaglutide, is less common but occurs due to insurance changes, availability issues, or side effect preferences
According to the STEP-1 clinical trial, patients who consumed semaglutide 2.4 mg once weekly experienced an average weight loss of 15% of their body weight after 68 weeks of treatment
While these won't fix loose skin, they improve the skin barrier, making the surface look smoother and more radiant
Priced by weekly dose, published up front